Anlong Bio Secures Hundreds of Millions RMB in Series A Financing Led by CITIC Healthcare Fund

VCBeat (WeChat: vcbeat) reports that Anlong has officially announced the completion of its Series A financing round, raising several hundred million RMB. The round was led by CITIC Medical Fund, with participation from Honghui Capital, Taiyu Investment, and Yuanlai Capital. Existing shareholders Tigermed and Haisong Capital continued to increase their follow-on investments. The proceeds will be primarily allocated to preclinical and clinical development, manufacturing system construction, and strategic partnerships. Anlong is committed to becoming a leading biopharmaceutical enterprise in China's gene therapy and nucleic acid therapeutics sector, delivering treatments tailored to the specific healthcare context of China.

Founded in 2019 by Dr. Zhao Chunlin, Anlong is headquartered at the Zhongguancun Translational Medicine Center in Shunyi District, Beijing. Dr. Zhao is a serial entrepreneur in the life sciences and healthcare sectors, with over three decades of experience spanning scientific research, multinational pharmaceutical enterprises, domestic startup ventures, and investment. Upon its establishment, the company secured an angel financing round of RMB 60 million, led by Tigermed.

Since its establishment, Anlong has adhered to a science-driven approach and an R&D-centric strategy, dedicated to building itself into a "leading Chinese biopharmaceutical enterprise in gene therapy and nucleic acid therapeutics." In collaboration with Tsinghua University, Capital Medical University, and other academic institutions, Anlong has established the Anlong Gene Therapy R&D Center. The company also operates a 5,000-square-meter R&D and GMP-compliant production facility at the Zhongguancun Medical Translation Center in Shunyi District, Beijing. Anlong holds distinct competitive advantages in gene therapy and nucleic acid drug design, preclinical research, CMC development, GMP manufacturing, viral vector production processes, large-scale manufacturing, and cost control. Furthermore, Anlong has integrated China's extensive rare disease resources and forged a strategic partnership with the Rare Disease Development Center, the nation's largest rare disease organization, laying a solid foundation for the future development and commercialization of its pipeline.

Dr. Zhao Chunlin, founder of Anlong, stated: “Broadly defined nucleic acid therapeutics (including gene therapy, small interfering RNA, etc.) will emerge as a novel drug development field that surpasses protein and antibody-based therapeutics. While nucleic acid therapeutic technology in the United States is already relatively mature, China's nucleic acid therapeutic sector remains in its nascent stage. From its inception to today, through rapid self-iteration, Anlong has officially entered a brand-new phase. I believe that China's protein and antibody drug sector can give rise to companies valued in the hundreds of billions, and the market scale for gene therapy and nucleic acid therapeutics will be even more immense. Anlong's goal is to become the leading enterprise in China's gene therapy and nucleic acid therapeutic sector.”

Ms. Cai Hua, General Manager of CITIC Healthcare Fund, stated: “Gene therapy and nucleic acid therapeutics have revolutionized the understanding of disease treatment over the past decade. Their success in European and American markets has further validated their technological reliability and immense commercial potential. Anlong possesses unique advantages in R&D and manufacturing, and I am confident that the team led by Dr. Zhao will achieve breakthroughs in this field and benefit patients.”

Honghui Capital (HLC) stated, “We are delighted to support the development of Anlong. Anlong boasts a robust R&D pipeline spanning multiple therapeutic areas, including ophthalmology and hematology, and is backed by a team with strong execution capabilities. HLC has previously collaborated with Dr. Zhao on multiple projects, and we are confident that under Dr. Zhao’s leadership, the Anlong team will drive further advancements in China’s nucleic acid therapeutics sector.”

`CITIC Healthcare Fund`It is CITIC’s equity investment management platform focused on the healthcare sector, dedicated to building a comprehensive, empowering healthcare industry fund with deep industry integration capabilities. The fund’s team comprises industry specialists with extensive senior operational experience at multinational pharmaceutical companies, alongside financial experts with profound expertise in the financial sector.

HLC (Honghui Capital)It is an asset management company with the mission of driving technological innovation, leveraging deep industry insights as its core competency, empowering key sectors such as healthcare and consumer industries, and creating long-term value. HLC's assets under management exceed RMB 10 billion, and it has established offices in Shanghai, Beijing, and Shenzhen.

Tigermed(Stock Code: 300347.SZ/3347.HK) is a leading comprehensive biopharmaceutical R&D service provider in China. Tigermed has established a complete biopharmaceutical R&D service system, maintains extensive, high-quality, and close relationships with clients and partners, and has consistently been a pioneer in the globalization of China's clinical contract research organizations (CROs), steadily expanding its global influence.

Haisong CapitalIt is a professional investment management institution dedicated to long-term and value investing. Haison Capital has invested in over thirty top-tier healthcare enterprises, with a strategic footprint spanning both China and the United States. By providing long-term, continuous support to outstanding entrepreneurs, and leveraging Haison’s international operational management expertise and extensive industry resources, the firm aims to accelerate corporate growth and jointly cultivate world-class, leading enterprises.

Taiyu InvestmentIt is an independent professional venture capital institution under the listed company Tigermed. Taiyu Investment focuses on equity investments in the early- and growth-stage healthcare sector. The management team possesses a deep background in the pharmaceutical and healthcare industry, extensive industry resources, and substantial investment experience. To date, it has completed early-stage equity investments totaling over RMB 1 billion across more than 60 projects in medical devices, biopharmaceuticals, and related fields.

Yuanlai CapitalHeadquartered in Shanghai and co-founded by leading figures in the investment sector, the firm currently manages its inaugural venture capital fund totaling approximately RMB 400 million. Backed by industry leaders such as Tigermed, it is dedicated to investments in the healthcare and core technology sectors.